GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Purple Biotech PPBT.TA · ILA

Health Care · Tel Aviv · 🇮🇱 Israel

Compare

1.00

—

Close of 26 Oct 2026, in ILA

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Revenue

—

FY2015FY2024

Net income

−$7.2m

FY2015FY2024

Free cash flow

−$14.4m

FY2015FY2024

Shareholders' equity

$32.9m

FY2015FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Revenue—————$1.0m$1.0m$100,000——
Gross profit—————$1.0m$1.0m$100,000——
Research and development$7.6m$17.0m$16.3m$11.8m$7.2m$2.7m$5.3m$4.6m$4.2m$2.6m
Operating income−$10.8m−$22.3m−$22.6m−$17.9m−$13.2m−$7.8m−$8.6m−$12.1m−$7.2m−$4.1m
Net income−$7.2m−$19.9m−$21.7m−$18.4m−$28.0m−$5.8m−$5.2m−$12.3m−$12.1m−$4.2m
Diluted earnings per share-0.02-0.08-0.12-0.10-0.25-0.30-0.32-1.14-1.60-1.08

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Total assets$37.0m$44.3m$54.6m$70.2m$83.8m$14.7m$14.7m$14.2m$14.9m$10.8m
Cash and short-term investments$8.5m$15.4m$32.1m$47.2m$57.8m—————
Total liabilities$4.2m$10.1m$7.7m$5.4m$4.4m$3.9m$3.7m$5.6m$1.5m$1.4m
Debt$183,000$351,000$515,000$749,000$895,000——$4.9m$758,000$845,000
Shareholders' equity$32.9m$34.2m$46.9m$64.8m$79.4m$10.4m$10.5m$7.3m$13.4m$9.4m
Shares outstanding328m252m181m176m115m19m16m11m8m4m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations−$14.4m−$19.9m−$16.7m−$15.3m−$13.8m−$5.6m−$8.5m−$8.6m−$6.3m−$3.3m
Capital spending—−$3,000−$228,000−$115,000−$156,000−$11,000−$16,000−$13,000−$10,000−$9,000
Free cash flow−$14.4m−$19.9m−$17.0m−$15.4m−$14.0m−$5.6m−$8.5m−$8.6m−$6.3m−$3.3m

Latest quarters

By quarter end

Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023
Operating income−$1.4m−$1.2m−$1.4m−$1.0m−$2.1m−$3.3m−$4.5m−$6.3m
Net income−$1.3m−$1.1m−$453,000−$410,000−$663,000−$2.4m−$3.8m−$4.8m
Diluted earnings per share-0.00-0.00-0.00——-0.01-0.01-0.01
Cash from operations−$1.0m−$1.0m−$1.0m−$2.0m−$3.0m−$3.0m−$5.0m−$4.0m
Total assets$39.1m$34.4m$35.6m$37.0m$35.1m$36.1m$39.9m$44.3m
Cash and short-term investments$10.5m$5.9m$7.1m$8.5m$6.3m$7.4m$10.9m$15.4m
Debt$49,000———$38,000$79,000$121,000$163,000
Shareholders' equity$32.8m$32.0m$32.6m$32.9m$29.4m$29.3m$31.0m$34.2m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-15.5%6.9%9.2%
Net income-26.7%4.4%3.3%

Valuation history

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Price to earnings-1.2-1.4-1.4-3.8-1.7-2.8-2.6-2.3-1.6-2.4
Price to sales—————16.613.8280.7——

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 30 Oct 2012.

FY2012
Paid in the year249.549
  • 20-to-1 reverse split · 6 Jan 2019
  • 13-to-1 reverse split · 30 Nov 2014
  • 100-to-1 reverse split · 24 Jun 2012

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.